LBA46 Bevacizumab (B) plus FOLFIRI after failure of platinum-etoposide in patients (pts) with advanced neuroendocrine carcinoma (NEC): The PRODIGE 41-BEVANEC randomized phase II study

Acte de colloque

Avec comité de lecture

Thomas Walter, A. Lievre, R. Coriat, D. Malka, F. El Hajbi, F. Di Fiore, O. Hentic Dhome, D. Smith, V. Hautefeuille, G. Roquin, …

Annals of oncology, Vol.33, p.S1412

Abstract Book of the ESMO Congress 2022, 9 - 13 September 2022

09/2022

Résumé

Cancer

Human health and pathology

Hépatology and Gastroenterology

Life Sciences

1 Consultations de la notice

Titre: LBA46 Bevacizumab (B) plus FOLFIRI after failure of platinum-etoposide in patients (pts) with advanced neuroendocrine carcinoma (NEC): The PRODIGE 41-BEVANEC randomized phase II study
Créateurs - sans rôle: Thomas Walter - Hospices Civils de Lyon
A. Lievre
R. Coriat
D. Malka
F. El Hajbi
F. Di Fiore
O. Hentic Dhome
D. Smith
V. Hautefeuille
G. Roquin
M. Perrier
L. Dahan
I. Sobhani
L. Mineur
P. Niccoli
E. Assenat
K. Le Malicot
C. Lepage
C. Lombard Bohas
Détails de publication: Annals of oncology, Vol.33, p.S1412
Colloque: Abstract Book of the ESMO Congress 2022, 9 - 13 September 2022
Identifiants: 99139656009311
Unité académique: Institut de Génétique Moléculaire de Montpellier - IGMM
Langue: English
Type de ressource: Conference proceeding